Skip to main content
Maria Escolar, MD, Pediatrics, Pittsburgh, PA

MariaLEscolarMD

Pediatrics Pittsburgh, PA

Neurodevelopmental Disabilities

Associate Professor, Pediatrics, University of Pittsburgh School of Medicine

Dr. Escolar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Escolar's full profile

Already have an account?

  • Office

    4401 Penn Avenue
    Pittsburgh, PA 15224

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1989 - 1993
  • Escuela Colombiana de Medicina
    Escuela Colombiana de MedicinaClass of 1986

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2011 - 2024
  • NC State Medical License
    NC State Medical License 1998 - 2012
  • NY State Medical License
    NY State Medical License 1993 - 2000

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium
    Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposiumFebruary 23rd, 2023
  • Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
    Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe DiseaseOctober 11th, 2022
  • Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual Symposium
    Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients with Krabbe Disease at the SSIEM Annual SymposiumAugust 30th, 2022
  • Join now to see all

Grant Support

  • DTI As A Tool To Identify Infants With Krabbe Disease In Need Of Urgent TreatmentNational Institute Of Neurological Disorders And Stroke2011–2012
  • DTI As A Tool To Identify Infants With Krabbe Disease In Need Of Urgent TreatmentNational Institute Of Neurological Disorders And Stroke2008–2011